MAPT and Alzheimer disease: The advent of cerebrospinal fluid (CSF) and fluorodeoxyglucose-positron emission tomography (FDG-PET) methods for the assessment of amyloid and tau has allowed the characterization of these more direct AD biomarkers to identify early stages and high-risk populations [32].